What is Nucleai?
Nucleai operates at the intersection of computational biology and clinical oncology. The company provides an AI-powered platform designed to analyze unique tissue datasets, thereby unlocking deeper insights into cancer biology. By licensing its research platform to leading pharmaceutical companies, Nucleai facilitates more efficient biomarker discovery and enhances the efficacy of clinical trials. This technology-driven approach is essential for modern drug development, as it allows researchers to identify patient populations that are most likely to respond to specific therapies, ultimately improving patient outcomes and streamlining the path to regulatory approval.
How much funding has Nucleai raised?
Nucleai has raised a total of $53.5M across 3 funding rounds:
Series A
$6.5M
Series B
$33M
Other Financing Round
$14M
Series A (2020): $6.5M with participation from Debiopharm Group companies, Grove Ventures Capital, and Vertex Ventures
Series B (2022): $33M led by Section 32 and Sanofi Ventures
Other Financing Round (2024): $14M supported by Merck Ventures
Key Investors in Nucleai
Section 32
A venture capital firm founded by Bill Maris that focuses on investing in cutting-edge technology and supporting visionary entrepreneurs at the forefront of innovation.
Sanofi Ventures
The corporate venture capital arm of Sanofi, specializing in early-stage biotech and digital health companies that align with their strategic interests in oncology and immunology.
Merck Ventures
The strategic corporate venture capital arm of Merck, focused on investing in transformational ideas and early-stage technologies that have the potential to impact core business areas.
What's next for Nucleai?
With the support of its latest strategic financing, Nucleai is well-positioned to scale its operations and deepen its collaborations within the pharmaceutical sector. The company is expected to leverage this capital to expand its proprietary dataset, refine its machine learning algorithms, and potentially enter new therapeutic areas beyond its current focus. As the demand for precision medicine continues to rise, Nucleai's ability to provide scalable, data-driven insights will be instrumental in shaping the future of oncology treatment. The firm remains focused on its long-term objective of integrating its platform into standard clinical workflows, thereby setting a new benchmark for precision medicine and therapeutic development.
See full Nucleai company page
